Tag: AVM
Latest TOBAS analysis finds low neurological event rate among conservatively managed...
Patients with unruptured brain arteriovenous malformations (AVMs) who are allocated to conservative management, or ‘observation’, experience a low rate of neurological events, according to...
ARISE I recommends multidisciplinary approach to managing brain aneurysms, chronic SDHs...
Three papers published in the journal Stroke have highlighted multidisciplinary care and global, collaborative efforts as “paramount” in the management of intracranial aneurysms, chronic...
Embolisation holds “very important, complementary” place in future of AVM treatment
After providing NeuroNews with an overview of the recent history of arteriovenous malformation (AVM) treatment in a previous video interview, Christophe Cognard (Toulouse University...
Growing evidence on AVM interventions contrasts with “horrible” ARUBA data
Recently, NeuroNews caught up with Christophe Cognard (Toulouse University Hospital, Toulouse, France) to discuss the current landscape of arteriovenous malformation (AVM) care. Cognard outlines...
New AVM intervention findings “refute” ARUBA complication rates and may elicit...
New data from an analysis of patients who would have been eligible for the ARUBA trial—which previously indicated medical management is likely favourable over...
New study finds surgical approaches safe and effective in ARUBA-eligible unruptured...
Contrary to the results of a seminal study in the field, a recent analysis presented at the Society of NeuroInterventional Surgery (SNIS) annual meeting...
Less invasive ‘liquid biopsy’ holds potential to identify genetic mutations in...
A study presented yesterday at the Society of NeuroInterventional Surgery (SNIS) annual meeting (31 July–4 August, San Diego, USA) indicates that it may be...
Pedro Lylyk
Pedro Lylyk’s work and achievements in the neurosurgical field have spanned several decades, and range from a momentous intracranial stent placement in 1996, to...
Wallaby Medical launches Avenir coil system for haemorrhagic stroke treatment in...
Wallaby Medical has partnered with Japan Lifeline (JLL) to bring its Pharmaceuticals and Medical Devices Agency (PMDA)-approved Avenir coil system to the Japanese market....
Phenox announces exclusive distribution agreement with Wallaby Medical for the Avenir...
Phenox announces that it has signed an exclusive distribution agreement with Wallaby Medical for commercialisation of the Avenir Detachable Coil System in the US...
Balt announces receiving CE mark for Magic Glue, a next generation...
Balt International has announced receiving the CE mark for Magic Glue, its next generation of cyanoacrylate liquid embolic agent. Magic Glue is indicated for...
